

**Supplementary Table 1.** Factors affecting overall survivals.

	Univariate		Multivariate	
	HR (95% CI)	<i>P</i>	HR (95% CI)	<i>P</i>
Age, continuous	1.03 (0.99–1.07)	0.181		
Gender, female vs. male	0.98 (0.41–2.30)	0.954		
Cytogenetic risk by MRC		0.063		
Favorable	1.00		-	
Intermediate	2.40 (0.54–10.56)	0.249	-	
Adverse	6.28 (1.20–32.99)	0.030	-	
<i>NPM1</i>				
Wild-type	1.00			
Mutated	0.57 (0.13–2.47)	0.456		
<i>FLT3</i> -ITD ratio				
Negative/low	1.00		-	
High	3.52 (1.11–11.12)	0.032	-	
<i>CEBPA</i>				
Wild-type/single	1.00		-	
Double mutation	0.24 (0.07–0.84)	0.025	-	NS
ELN risk group		0.008		0.019
Favorable	1.00		1.00	
Intermediate-other	6.11 (0.61–61.45)	0.124	5.42 (0.53–55.49)	0.155
Intermediate-both negative	2.13 (0.58–7.88)	0.257	1.65 (0.43–6.29)	0.462
Adverse	7.93 (2.08–30.23)	0.002	6.36 (1.61–25.05)	0.008
Response to primary induction				
Complete remission	1.00		1.00	
Primary refractory	3.48 (1.49–8.11)	0.004	2.95 (1.22–7.14)	0.017
Performance of allogeneic HCT	1.04 (0.93–1.17)	0.504		

Abbreviations: *CEBPA*, CCAAT/enhancer binding protein  $\alpha$ ; CI, confidence interval; ELN, European LeukemiaNet; *FLT3*-ITD, fms-like tyrosine kinase 3-internal tandem duplication; HCT, hematopoietic cell transplantation; HR, hazard ratio; *NPM1*, nucleophosmin 1.